Treatment strategies for acute pulmonary embolism

被引：2

作者：

Blondon, Marc ^{[1
,2
]}

Bounameaux, Henri ^{[1
,3
]}

Righini, Marc ^{[1
,3
]}

机构：

[1] Univ Hosp Geneva, CH-1211 Geneva 14, Switzerland

[2] Fac Med, Dept Internal Med, Div Gen Internal Med, CH-1211 Geneva 14, Switzerland

[3] Fac Med, Dept Internal Med, Div Angiol & Hemostasis, Geneva, Switzerland

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2009年 / 10卷 / 07期

关键词：

anticoagulation; factor Xa inhibitors; pulmonary embolism; thrombin inhibitors; treatment; venous thromboembolism; DEEP-VEIN THROMBOSIS; ORAL ANTICOAGULANT-THERAPY; MOLECULAR-WEIGHT HEPARIN; RECURRENT VENOUS THROMBOEMBOLISM; INTRAVENOUS UNFRACTIONATED HEPARIN; INTENSITY WARFARIN THERAPY; BRAIN NATRIURETIC PEPTIDE; XA INHIBITOR RIVAROXABAN; OUTPATIENT TREATMENT; INITIAL TREATMENT;

D O I：

10.1517/14656560902911470

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Acute pulmonary embolism (PE) is a life-threatening condition that has been treated with anticoagulation for almost 50 years. Objectives: To review the current treatment options for PE and discuss recently published new features. Methods: We reviewed literature involving the treatment strategies for venous thromboembolism (VTE) and in particular pulmonary embolism. Specific attention was drawn towards the evidence of the present treatment and of drugs being studied in Phase III trials. Results/conclusions: Treatment of acute PE consists of parenteral administration of heparin, low-molecular-weight heparin or fondaparinux overlapped and followed by oral vitamin K antagonists for a minimum of 3 months. Contemporary features include the emergence of new anticoagulant drugs such as oral synthetic inhibitors of thrombin or factor Xa. The duration of anticoagulation for unprovoked VTE remains highly debated.

引用

页码：1159 / 1171

页数：13

共 84 条

[1] Extended oral anticoagulant therapy after a first episode of pulmonary embolism [J].

Agnelli, G ;

Prandoni, P ;

Becattini, C ;

Silingardi, M ;

Taliani, MR ;

Miccio, M ;

Imberti, D ;

Poggio, R ;

Ageno, W ;

Pogliani, E ;

Porro, F ;

Zonzin, P .

ANNALS OF INTERNAL MEDICINE, 2003, 139 (01) :19-25

[2] Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. [J].

Agnelli, G ;

Prandoni, P ;

Santamaria, MG ;

Bagatella, P ;

Iorio, A ;

Bazzan, M ;

Moia, M ;

Guazzaloca, G ;

Bertoldi, A ;

Tomasi, C ;

Scannapieco, G ;

Ageno, W ;

Ascani, A ;

Villalta, S ;

Frulla, M ;

Mosena, L ;

Girolami, A ;

Vaccarino, A ;

Alatri, A ;

Palareti, G ;

Marchesi, M ;

Ambrosio, GB ;

Parisi, R ;

Doria, S ;

Steidl, L ;

Ambrosini, F ;

Silingardi, M ;

Ghirarduzzi, A ;

Iori, I .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :165-169

[3]

AGNELLI G, TENECTEPLASE PULMONA

[4] Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939) - The ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study [J].

Agnelli, Giancarlo ;

Gallus, Alexander ;

Goldhaber, Samuel Z. ;

Haas, Sylvia ;

Huisman, Menno V. ;

Hull, Russel D. ;

Kakkar, Ajay K. ;

Misselwitz, Frank ;

Schellong, Sebastian .

CIRCULATION, 2007, 116 (02) :180-187

[5] Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer [J].

Akl, E. A. ;

Barba, M. ;

Rohilla, S. ;

Terrenato, I ;

Sperati, F. ;

Muti, P. ;

Schuenemann, H. J. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (02)

[6] Acute pulmonary embolectomy - A contemporary approach [J].

Aklog, L ;

Williams, CS ;

Byrne, JG ;

Goldhaber, SZ .

CIRCULATION, 2002, 105 (12) :1416-1419

[7] Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia [J].

Amiral, J ;

Lormeau, JC ;

MarfaingKoka, A ;

Vissac, AM ;

Wolf, M ;

BoyerNeumann, C ;

Tardy, B ;

Herbert, JM ;

Meyer, D .

BLOOD COAGULATION & FIBRINOLYSIS, 1997, 8 (02) :114-117

[8] Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation [J].

Anderson, Jeffrey L. ;

Horne, Benjamin D. ;

Stevens, Scott M. ;

Grove, Amanda S. ;

Barton, Stephanie ;

Nicholas, Zachery P. ;

Kahn, Samera F. S. ;

May, Heidi T. ;

Samuelson, Kent M. ;

Muhlestein, Joseph B. ;

Carlquist, John F. .

CIRCULATION, 2007, 116 (22) :2563-2570

[9] Heparin-induced thrombocytopenia [J].

Arepally, Gowthami M. ;

Ortel, Thomas L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (08) :809-817

[10] A prediction rule to identify low-risk patients with pulmonary embolism [J].

Aujesky, D ;

Obrosky, DS ;

Stone, RA ;

Auble, TE ;

Perrier, A ;

Cornuz, J ;

Roy, PM ;

Fine, MJ .

ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (02) :169-175

← 1 2 3 4 5 6 7 8 9 →